Parke-Davis Pharmaceutical Research other research news

Parke-Davis reported on an inhibitor of epidermal growth factor (EGF) receptor, showing that the potency of the small molecule PD 153035 in blocking the isolated EGF receptor's tyrosine kinase was four to five orders of magnitude greater than other tyrosine kinase inhibitors.

The receptor is implicated in cancer, the researchers noted, as a correlation exists between the amount of receptor and poor prognosis. ...